There are multiple tissue sources for MSC's Bone Marrow, Adipose(Fat), Umbilical Cord etc
Beyond our Remestemcel product we have licenced our patents to Tigenix / Takeda for their Alofisel / CX601 cell line which is derived from Adipose tissue. These are being used in the Spanish 100 Patient Covid-19 trial. If that is successful and gets commercialised we will get revenues from that stream as well.
I read a paper last week that was testing BM derived MSC's from Hip Replacement donors (simply because it was readily available and the donors were happy to consent). Surprisingly they seemed in to be equivalent in efficacy to young, healthy donor derived cells...
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-807
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |